Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

The stock's fall snapped a two-day winning streak.

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

The latest trend in health and fitness tracking may sound familiar: wearing continuous glucose monitors (CGMs). Many people ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes | Dexcom ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...